APO Research
Talk to an analyst

APO RESEARCH · REPORT

Radiopharmaceutical

Radiopharmaceuticals are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Radiopharmaceuticals are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.

Selected research

Market Outlook & Growth Opportunities

Global Radiopharmaceutical Market Outlook and Growth Opportunities 2026

25 December 2025194 pages

Choose your research edition.

Industry ResearchRadiopharmaceutical Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal Radiopharmaceutical Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Radiopharmaceutical Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Radiopharmaceutical Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Radiopharmaceutical Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Radiopharmaceuticals are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.

The global Radiopharmaceutical top three manufacturers include the Bracco Imaging, Bayer and Mallinckrodt, with about 47% market shares. North America and Europe is the main consumption places, with a consumption market share nearly 45% and 27%.

This report provides an overview of the global Radiopharmaceutical market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Radiopharmaceutical and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Radiopharmaceutical sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Radiopharmaceutical market size, projected growth trends, production technologies, key applications, and end-use industries.

Radiopharmaceutical Segment by Company

Bracco Imaging

Bayer

Mallinckrodt

Nordion

Triad Isotopes

Lantheus

IBA Group

GE Healthcare

China Isotope & Radiation

Jubilant Pharma

Eli Lilly

Advanced Accelerator Applications

SIEMENS

Dongcheng

Navidea

Radiopharmaceutical Segment by Type

Actinium-225

Lutetium-177

Radium-223

Holmium-166

Other

Radiopharmaceutical Segment by Application

Oncology

Cardiology

Other

Radiopharmaceutical Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Radiopharmaceutical status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Radiopharmaceutical market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Radiopharmaceutical significant trends, drivers, influence factors in global and regions.

6. To analyze Radiopharmaceutical competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceutical market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceutical and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceutical.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Radiopharmaceutical market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Radiopharmaceutical industry.

Chapter 3: Detailed analysis of Radiopharmaceutical manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Radiopharmaceutical in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Radiopharmaceutical in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Radiopharmaceutical Industry Trends Table 2. Radiopharmaceutical Industry Drivers Table 3. Radiopharmaceutical Industry Opportunities and Challenges Table 4. Radiopharmaceutical Industry Restraints Table 5. Global Radiopharmaceutical Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Radiopharmaceutical Revenue Share by Company (2021-2026) Table 7. Global Radiopharmaceutical Sales Volume by Company (M Doses) & (2021-2026) Table 8. Global Radiopharmaceutical Sales Volume Share by Company (2021-2026) Table 9. Global Radiopharmaceutical Average Price (USD/Dose) of Company (2021-2026) Table 10. Global Radiopharmaceutical Company Ranking, (2024-2026) & (USD Million) Table 11. Global Radiopharmaceutical Key Company Manufacturing Base & Headquarters Table 12. Global Radiopharmaceutical Company, Product Type & Application Table 13. Global Radiopharmaceutical Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Radiopharmaceutical by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Actinium-225 Table 18. Significant Companies of Lutetium-177 Table 19. Significant Companies of Radium-223 Table 20. Significant Companies of Holmium-166 Table 21. Significant Companies of Other Table 22. Global Radiopharmaceutical Sales Volume by Type 2021 VS 2025 VS 2032 (M Doses) Table 23. Global Radiopharmaceutical Sales Volume by Type (2021-2026) & (M Doses) Table 24. Global Radiopharmaceutical Sales Volume by Type (2027-2032) & (M Doses) Table 25. Global Radiopharmaceutical Sales Volume Share by Type (2021-2026) Table 26. Global Radiopharmaceutical Sales Volume Share by Type (2027-2032) Table 27. Global Radiopharmaceutical Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Radiopharmaceutical Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Radiopharmaceutical Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Radiopharmaceutical Sales Value Share by Type (2021-2026) Table 31. Global Radiopharmaceutical Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Oncology Table 33. Significant Companies of Cardiology Table 34. Significant Companies of Other Table 35. Global Radiopharmaceutical Sales Volume by Application 2021 VS 2025 VS 2032 (M Doses) Table 36. Global Radiopharmaceutical Sales Volume by Application (2021-2026) & (M Doses) Table 37. Global Radiopharmaceutical Sales Volume by Application (2027-2032) & (M Doses) Table 38. Global Radiopharmaceutical Sales Volume Share by Application (2021-2026) Table 39. Global Radiopharmaceutical Sales Volume Share by Application (2027-2032) Table 40. Global Radiopharmaceutical Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Radiopharmaceutical Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Radiopharmaceutical Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Radiopharmaceutical Sales Value Share by Application (2021-2026) Table 44. Global Radiopharmaceutical Sales Value Share by Application (2027-2032) Table 45. Global Radiopharmaceutical Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Table 46. Global Radiopharmaceutical Sales by Region (2021-2026) & (M Doses) Table 47. Global Radiopharmaceutical Sales Market Share by Region (2021-2026) Table 48. Global Radiopharmaceutical Sales by Region (2027-2032) & (M Doses) Table 49. Global Radiopharmaceutical Sales Market Share by Region (2027-2032) Table 50. Global Radiopharmaceutical Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Radiopharmaceutical Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Radiopharmaceutical Sales Value Share by Region (2021-2026) Table 53. Global Radiopharmaceutical Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Radiopharmaceutical Sales Value Share by Region (2027-2032) Table 55. Global Radiopharmaceutical Market Average Price (USD/Dose) by Region (2021-2026) Table 56. Global Radiopharmaceutical Market Average Price (USD/Dose) by Region (2027-2032) Table 57. Global Radiopharmaceutical Sales by Country: 2021 VS 2025 VS 2032 (M Doses) Table 58. Global Radiopharmaceutical Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Radiopharmaceutical Sales by Country (2021-2026) & (M Doses) Table 60. Global Radiopharmaceutical Sales Market Share by Country (2021-2026) Table 61. Global Radiopharmaceutical Sales by Country (2027-2032) & (M Doses) Table 62. Global Radiopharmaceutical Sales Market Share by Country (2027-2032) Table 63. Global Radiopharmaceutical Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Radiopharmaceutical Sales Value Market Share by Country (2021-2026) Table 65. Global Radiopharmaceutical Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Radiopharmaceutical Sales Value Market Share by Country (2027-2032) Table 67. Bracco Imaging Company Information Table 68. Bracco Imaging Business Overview Table 69. Bracco Imaging Radiopharmaceutical Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 70. Bracco Imaging Radiopharmaceutical Product Portfolio Table 71. Bracco Imaging Recent Development Table 72. Bayer Company Information Table 73. Bayer Business Overview Table 74. Bayer Radiopharmaceutical Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 75. Bayer Radiopharmaceutical Product Portfolio Table 76. Bayer Recent Development Table 77. Mallinckrodt Company Information Table 78. Mallinckrodt Business Overview Table 79. Mallinckrodt Radiopharmaceutical Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 80. Mallinckrodt Radiopharmaceutical Product Portfolio Table 81. Mallinckrodt Recent Development Table 82. Nordion Company Information Table 83. Nordion Business Overview Table 84. Nordion Radiopharmaceutical Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 85. Nordion Radiopharmaceutical Product Portfolio Table 86. Nordion Recent Development Table 87. Triad Isotopes Company Information Table 88. Triad Isotopes Business Overview Table 89. Triad Isotopes Radiopharmaceutical Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 90. Triad Isotopes Radiopharmaceutical Product Portfolio Table 91. Triad Isotopes Recent Development Table 92. Lantheus Company Information Table 93. Lantheus Business Overview Table 94. Lantheus Radiopharmaceutical Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 95. Lantheus Radiopharmaceutical Product Portfolio Table 96. Lantheus Recent Development Table 97. IBA Group Company Information Table 98. IBA Group Business Overview Table 99. IBA Group Radiopharmaceutical Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 100. IBA Group Radiopharmaceutical Product Portfolio Table 101. IBA Group Recent Development Table 102. GE Healthcare Company Information Table 103. GE Healthcare Business Overview Table 104. GE Healthcare Radiopharmaceutical Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 105. GE Healthcare Radiopharmaceutical Product Portfolio Table 106. GE Healthcare Recent Development Table 107. China Isotope & Radiation Company Information Table 108. China Isotope & Radiation Business Overview Table 109. China Isotope & Radiation Radiopharmaceutical Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 110. China Isotope & Radiation Radiopharmaceutical Product Portfolio Table 111. China Isotope & Radiation Recent Development Table 112. Jubilant Pharma Company Information Table 113. Jubilant Pharma Business Overview Table 114. Jubilant Pharma Radiopharmaceutical Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 115. Jubilant Pharma Radiopharmaceutical Product Portfolio Table 116. Jubilant Pharma Recent Development Table 117. Eli Lilly Company Information Table 118. Eli Lilly Business Overview Table 119. Eli Lilly Radiopharmaceutical Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 120. Eli Lilly Radiopharmaceutical Product Portfolio Table 121. Eli Lilly Recent Development Table 122. Advanced Accelerator Applications Company Information Table 123. Advanced Accelerator Applications Business Overview Table 124. Advanced Accelerator Applications Radiopharmaceutical Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 125. Advanced Accelerator Applications Radiopharmaceutical Product Portfolio Table 126. Advanced Accelerator Applications Recent Development Table 127. SIEMENS Company Information Table 128. SIEMENS Business Overview Table 129. SIEMENS Radiopharmaceutical Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 130. SIEMENS Radiopharmaceutical Product Portfolio Table 131. SIEMENS Recent Development Table 132. Dongcheng Company Information Table 133. Dongcheng Business Overview Table 134. Dongcheng Radiopharmaceutical Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 135. Dongcheng Radiopharmaceutical Product Portfolio Table 136. Dongcheng Recent Development Table 137. Navidea Company Information Table 138. Navidea Business Overview Table 139. Navidea Radiopharmaceutical Sales (M Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 140. Navidea Radiopharmaceutical Product Portfolio Table 141. Navidea Recent Development Table 142. Key Raw Materials Table 143. Raw Materials Key Suppliers Table 144. Radiopharmaceutical Distributors List Table 145. Radiopharmaceutical Customers List Table 146. Research Programs/Design for This Report Table 147. Authors List of This Report Table 148. Secondary Sources Table 149. Primary Sources List of Figures Figure 1. Radiopharmaceutical Product Image Figure 2. Global Radiopharmaceutical Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Radiopharmaceutical Sales Value (2021-2032) & (US$ Million) Figure 4. Global Radiopharmaceutical Sales (2021-2032) & (M Doses) Figure 5. Global Radiopharmaceutical Sales Average Price (USD/Dose) & (2021-2032) Figure 6. Global Radiopharmaceutical Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Actinium-225 Image Figure 10. Lutetium-177 Image Figure 11. Radium-223 Image Figure 12. Holmium-166 Image Figure 13. Other Image Figure 14. Global Radiopharmaceutical Sales Volume by Type (2021 VS 2025 VS 2032) & (M Doses) Figure 15. Global Radiopharmaceutical Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Radiopharmaceutical Sales Volume Share by Type (2021-2032) Figure 17. Global Radiopharmaceutical Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Radiopharmaceutical Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Radiopharmaceutical Sales Value Share by Type (2021-2032) Figure 20. Oncology Image Figure 21. Cardiology Image Figure 22. Other Image Figure 23. Global Radiopharmaceutical Sales Volume by Application (2021 VS 2025 VS 2032) & (M Doses) Figure 24. Global Radiopharmaceutical Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Radiopharmaceutical Sales Volume Share by Application (2021-2032) Figure 26. Global Radiopharmaceutical Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Radiopharmaceutical Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Radiopharmaceutical Sales Value Share by Application (2021-2032) Figure 29. Global Radiopharmaceutical Sales by Region: 2021 VS 2025 VS 2032 (M Doses) Figure 30. Global Radiopharmaceutical Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Radiopharmaceutical Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Radiopharmaceutical Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Radiopharmaceutical Sales Value (2021-2032) & (US$ Million) Figure 34. North America Radiopharmaceutical Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Radiopharmaceutical Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Radiopharmaceutical Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Radiopharmaceutical Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Radiopharmaceutical Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Radiopharmaceutical Sales Value (2021-2032) & (US$ Million) Figure 40. South America Radiopharmaceutical Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Radiopharmaceutical Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Radiopharmaceutical Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Radiopharmaceutical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Radiopharmaceutical Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Radiopharmaceutical Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Actinium-225
  • Lutetium-177
  • Radium-223
  • Holmium-166
  • Other
Applications
  • Oncology
  • Cardiology
  • Other
Companies covered
  • Bracco Imaging
  • Bayer
  • Mallinckrodt
  • Nordion
  • Triad Isotopes
  • Lantheus
  • IBA Group
  • GE Healthcare
  • China Isotope & Radiation
  • Jubilant Pharma
  • Eli Lilly
  • Advanced Accelerator Applications
  • SIEMENS
  • Dongcheng
  • Navidea

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Radiopharmaceutical Sales Value (2021-2032)
  4. 1.2.2 Global Radiopharmaceutical Sales Volume (2021-2032)
  5. 1.2.3 Global Radiopharmaceutical Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Radiopharmaceutical Market Dynamics
  1. 2.1 Radiopharmaceutical Industry Trends
  2. 2.2 Radiopharmaceutical Industry Drivers
  3. 2.3 Radiopharmaceutical Industry Opportunities and Challenges
  4. 2.4 Radiopharmaceutical Industry Restraints
3 Radiopharmaceutical Market by Company
  1. 3.1 Global Radiopharmaceutical Company Revenue Ranking in 2025
  2. 3.2 Global Radiopharmaceutical Revenue by Company (2021-2026)
  3. 3.3 Global Radiopharmaceutical Sales Volume by Company (2021-2026)
  4. 3.4 Global Radiopharmaceutical Average Price by Company (2021-2026)
  5. 3.5 Global Radiopharmaceutical Company Ranking (2024-2026)
  6. 3.6 Global Radiopharmaceutical Company Manufacturing Base and Headquarters
  7. 3.7 Global Radiopharmaceutical Company Product Type and Application
  8. 3.8 Global Radiopharmaceutical Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Radiopharmaceutical Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Radiopharmaceutical Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Radiopharmaceutical Market by Type
  1. 4.1 Radiopharmaceutical Type Introduction
  2. 4.1.1 Actinium-225
  3. 4.1.2 Lutetium-177
  4. 4.1.3 Radium-223
  5. 4.1.4 Holmium-166
  6. 4.1.5 Other
  7. 4.2 Global Radiopharmaceutical Sales Volume by Type
  8. 4.2.1 Global Radiopharmaceutical Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Radiopharmaceutical Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Radiopharmaceutical Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Radiopharmaceutical Sales Value by Type
  12. 4.3.1 Global Radiopharmaceutical Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Radiopharmaceutical Sales Value by Type (2021-2032)
  14. 4.3.3 Global Radiopharmaceutical Sales Value Share by Type (2021-2032)
5 Radiopharmaceutical Market by Application
  1. 5.1 Radiopharmaceutical Application Introduction
  2. 5.1.1 Oncology
  3. 5.1.2 Cardiology
  4. 5.1.3 Other
  5. 5.2 Global Radiopharmaceutical Sales Volume by Application
  6. 5.2.1 Global Radiopharmaceutical Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Radiopharmaceutical Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Radiopharmaceutical Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Radiopharmaceutical Sales Value by Application
  10. 5.3.1 Global Radiopharmaceutical Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Radiopharmaceutical Sales Value by Application (2021-2032)
  12. 5.3.3 Global Radiopharmaceutical Sales Value Share by Application (2021-2032)
6 Radiopharmaceutical Regional Sales and Value Analysis
  1. 6.1 Global Radiopharmaceutical Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Radiopharmaceutical Sales by Region (2021-2032)
  3. 6.2.1 Global Radiopharmaceutical Sales by Region: 2021-2026
  4. 6.2.2 Global Radiopharmaceutical Sales by Region (2027-2032)
  5. 6.3 Global Radiopharmaceutical Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Radiopharmaceutical Sales Value by Region (2021-2032)
  7. 6.4.1 Global Radiopharmaceutical Sales Value by Region: 2021-2026
  8. 6.4.2 Global Radiopharmaceutical Sales Value by Region (2027-2032)
  9. 6.5 Global Radiopharmaceutical Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Radiopharmaceutical Sales Value (2021-2032)
  12. 6.6.2 North America Radiopharmaceutical Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Radiopharmaceutical Sales Value (2021-2032)
  15. 6.7.2 Europe Radiopharmaceutical Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Radiopharmaceutical Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Radiopharmaceutical Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Radiopharmaceutical Sales Value (2021-2032)
  21. 6.9.2 South America Radiopharmaceutical Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Radiopharmaceutical Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Radiopharmaceutical Sales Value Share by Country, 2025 VS 2032
7 Radiopharmaceutical Country-level Sales and Value Analysis
  1. 7.1 Global Radiopharmaceutical Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Radiopharmaceutical Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Radiopharmaceutical Sales by Country (2021-2032)
  4. 7.3.1 Global Radiopharmaceutical Sales by Country (2021-2026)
  5. 7.3.2 Global Radiopharmaceutical Sales by Country (2027-2032)
  6. 7.4 Global Radiopharmaceutical Sales Value by Country (2021-2032)
  7. 7.4.1 Global Radiopharmaceutical Sales Value by Country (2021-2026)
  8. 7.4.2 Global Radiopharmaceutical Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Radiopharmaceutical Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Radiopharmaceutical Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Radiopharmaceutical Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bracco Imaging
  2. 8.1.1 Bracco Imaging Company Information
  3. 8.1.2 Bracco Imaging Business Overview
  4. 8.1.3 Bracco Imaging Radiopharmaceutical Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bracco Imaging Radiopharmaceutical Product Portfolio
  6. 8.1.5 Bracco Imaging Recent Developments
  7. 8.2 Bayer
  8. 8.2.1 Bayer Company Information
  9. 8.2.2 Bayer Business Overview
  10. 8.2.3 Bayer Radiopharmaceutical Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Radiopharmaceutical Product Portfolio
  12. 8.2.5 Bayer Recent Developments
  13. 8.3 Mallinckrodt
  14. 8.3.1 Mallinckrodt Company Information
  15. 8.3.2 Mallinckrodt Business Overview
  16. 8.3.3 Mallinckrodt Radiopharmaceutical Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Mallinckrodt Radiopharmaceutical Product Portfolio
  18. 8.3.5 Mallinckrodt Recent Developments
  19. 8.4 Nordion
  20. 8.4.1 Nordion Company Information
  21. 8.4.2 Nordion Business Overview
  22. 8.4.3 Nordion Radiopharmaceutical Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Nordion Radiopharmaceutical Product Portfolio
  24. 8.4.5 Nordion Recent Developments
  25. 8.5 Triad Isotopes
  26. 8.5.1 Triad Isotopes Company Information
  27. 8.5.2 Triad Isotopes Business Overview
  28. 8.5.3 Triad Isotopes Radiopharmaceutical Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Triad Isotopes Radiopharmaceutical Product Portfolio
  30. 8.5.5 Triad Isotopes Recent Developments
  31. 8.6 Lantheus
  32. 8.6.1 Lantheus Company Information
  33. 8.6.2 Lantheus Business Overview
  34. 8.6.3 Lantheus Radiopharmaceutical Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Lantheus Radiopharmaceutical Product Portfolio
  36. 8.6.5 Lantheus Recent Developments
  37. 8.7 IBA Group
  38. 8.7.1 IBA Group Company Information
  39. 8.7.2 IBA Group Business Overview
  40. 8.7.3 IBA Group Radiopharmaceutical Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 IBA Group Radiopharmaceutical Product Portfolio
  42. 8.7.5 IBA Group Recent Developments
  43. 8.8 GE Healthcare
  44. 8.8.1 GE Healthcare Company Information
  45. 8.8.2 GE Healthcare Business Overview
  46. 8.8.3 GE Healthcare Radiopharmaceutical Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 GE Healthcare Radiopharmaceutical Product Portfolio
  48. 8.8.5 GE Healthcare Recent Developments
  49. 8.9 China Isotope & Radiation
  50. 8.9.1 China Isotope & Radiation Company Information
  51. 8.9.2 China Isotope & Radiation Business Overview
  52. 8.9.3 China Isotope & Radiation Radiopharmaceutical Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 China Isotope & Radiation Radiopharmaceutical Product Portfolio
  54. 8.9.5 China Isotope & Radiation Recent Developments
  55. 8.10 Jubilant Pharma
  56. 8.10.1 Jubilant Pharma Company Information
  57. 8.10.2 Jubilant Pharma Business Overview
  58. 8.10.3 Jubilant Pharma Radiopharmaceutical Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Jubilant Pharma Radiopharmaceutical Product Portfolio
  60. 8.10.5 Jubilant Pharma Recent Developments
  61. 8.11 Eli Lilly
  62. 8.11.1 Eli Lilly Company Information
  63. 8.11.2 Eli Lilly Business Overview
  64. 8.11.3 Eli Lilly Radiopharmaceutical Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Eli Lilly Radiopharmaceutical Product Portfolio
  66. 8.11.5 Eli Lilly Recent Developments
  67. 8.12 Advanced Accelerator Applications
  68. 8.12.1 Advanced Accelerator Applications Company Information
  69. 8.12.2 Advanced Accelerator Applications Business Overview
  70. 8.12.3 Advanced Accelerator Applications Radiopharmaceutical Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Advanced Accelerator Applications Radiopharmaceutical Product Portfolio
  72. 8.12.5 Advanced Accelerator Applications Recent Developments
  73. 8.13 SIEMENS
  74. 8.13.1 SIEMENS Company Information
  75. 8.13.2 SIEMENS Business Overview
  76. 8.13.3 SIEMENS Radiopharmaceutical Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 SIEMENS Radiopharmaceutical Product Portfolio
  78. 8.13.5 SIEMENS Recent Developments
  79. 8.14 Dongcheng
  80. 8.14.1 Dongcheng Company Information
  81. 8.14.2 Dongcheng Business Overview
  82. 8.14.3 Dongcheng Radiopharmaceutical Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Dongcheng Radiopharmaceutical Product Portfolio
  84. 8.14.5 Dongcheng Recent Developments
  85. 8.15 Navidea
  86. 8.15.1 Navidea Company Information
  87. 8.15.2 Navidea Business Overview
  88. 8.15.3 Navidea Radiopharmaceutical Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Navidea Radiopharmaceutical Product Portfolio
  90. 8.15.5 Navidea Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Radiopharmaceutical Value Chain Analysis
  2. 9.1.1 Radiopharmaceutical Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Radiopharmaceutical Sales Mode & Process
  6. 9.2 Radiopharmaceutical Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Radiopharmaceutical Distributors
  9. 9.2.3 Radiopharmaceutical Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst